No Pressure: FDA Floats Threshold On Adverse Blood Pressure Effect In Chronic Drugs
Executive Summary
Revised draft guidance proposes that sponsors of new drugs intended for chronic use should rule out a 3-mmHg blood pressure increase in pre-market trials.